Infectious complications following probiotic ingestion: A potentially underestimated problem? A systematic review of reports and case series

BMC Complementary and Alternative Medicine

Volumn 18, Issue 1, 2018, Pages

  Costa, Rafael Lessa ^a,b,c   Moreira, José ^c,e   Lorenzo, Andrea ^c   Lamas, Cristiane C ^c,d,e  

^a Hospital da UNIMED   (Brazil)

^b Cardiointensive Unit of Americas Medical City   (Brazil)

^c Dyslipidemia and Atherosclerosis of Ambulatório National Institute of Cardiology   (Brazil)

^d Unigranrio University   (Brazil)

^e Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Fungemia; Infection; Lactobacillus; Probiotics; Saccharomyces; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOSUPPRESSIVE AGENT; PROBIOTIC AGENT;

ABSCESS; AGE DISTRIBUTION; ALL CAUSE MORTALITY; ARTICLE; BACILLUS SUBTILIS; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS; CLOSTRIDIUM DIFFICILE INFECTION; DRUG SAFETY; DRUG USE; ENDOCARDITIS; ENTERIC FEEDING; ESCHERICHIA; FUNGEMIA; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS COMPLICATION; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS PARACASEI; LACTOBACILLUS RHAMNOSUS; MORTALITY RATE; NONHUMAN; ORGAN TRANSPLANTATION; PARENTERAL NUTRITION; PEDIOCOCCUS; PLEURA EMPYEMA; PNEUMONIA; RISK FACTOR; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE; SEPSIS; SEX RATIO; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; AGED; BIFIDOBACTERIUM; CHILD; FEMALE; GRAM POSITIVE INFECTION; INFANT; LACTOBACILLUS; MALE; MICROBIOLOGY; MIDDLE AGED; MYCOSIS; NEWBORN; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; SACCHAROMYCES; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIFIDOBACTERIUM; CHILD; CHILD, PRESCHOOL; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; LACTOBACILLUS; MALE; MIDDLE AGED; MYCOSES; PROBIOTICS; SACCHAROMYCES; YOUNG ADULT;

EID: 85058590037     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-018-2394-3     Document Type: Article

References (25)

1. FAO/WHO. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report, 2001.
2. Manzanares W, Lemieux M, Langlois P, Wischmeyer P. Probiotic and symbiotic therapy in critical illness: a systematic review and meta-analysis. Crit Care. 2016. https://doi.org/10.1186/s13054-016-1434-y.
3. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst. 2004;2:1-9.
4. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, Matuchansky C. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicenter, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26:475-86.
5. Aki MK, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet. 2001;357(9262):1076-9.
6. Zhang Q, Wu Y, Fei X. Effect of probiotics on body weight and body-mass index: a systematic review and meta-analysis of randomized, controlled trials. Int J Food Sci Nutr. 2015;67(5):571-80.
7. Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, Sarna S, Valtonen V, Järvinen A. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 2002;35:1155-60.
8. Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JNV, Suttorp MJ, Johnsen B, Shanman R, Slusser W, Fu N, Smith A, Roth E, Polak J, Motala A, Perry T, Shekelle PG. Safety of probiotics to reduce risk and prevent or treat disease. Evidence report. Rockville: Southern California Evidence-based Practice Center; 2011. Report No.: 11-E007. Contrat No.: 290-2007-10062-I. Sponsored by Agency for Healthcare Research and Quality
9. Liberati A, Altman DG, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):1-34.
10. Munford RS. Sepsis, severe sepsis and septic shock. In: Bennett JE, Dolin R, Blaser MJ, editors. Principles and practice of infectious diseases. 6th ed. New York: Elsevier Churchill Livingstone publishers; 2005. p. 906-26.
11. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. ACCP/SCCM consensus conference: definitions for sepse and organ failure and guidelines for the use of innovative therapies in sepse. Crit Care Med. 1992;20:864-74.
12. Durack DT, Lukes AS, Bright DJ, the Duke Endocarditis Service. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiografic findings. Am J Med. 1994;96:200-9.
13. Health Sciences Descriptors. Virtual library in health. 2016. http://decs.bvs.br/cgi-bin/wxis1660.exe/decsserver/. Acessed 28 June 2016.
14. NIH. Quality assessment tool for case series studies. In: National Heart, Lung, and Blood Institute; 2014. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Acessed 28 June 2016.
15. Munõz P, Bouza E, Cuenca-Estrella M, Eiros JM, Pérez MJ, Sánchez-Somolinos M, Rincón C, Hortal J, Peláez T. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40(1):1625-34.
16. Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect. 2014;20(Suppl. 3):76-98.
17. Avcin SL, Pokorn MP, Kitanovski L, Premru MM, Jazbec J. Bifidobacterium breve sepsis in child with high-risk acute lymphoblastic leukemia. Emerg Infect Dis. 2015;21(9):1674-5.
18. LeDoux D, LaBombardi VJ, Karter D. Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease. Int J STD AIDS. 2006;17(4):280-2.
19. Antony S. Lactobacillemia: an emerging cause of infection in both the immunocompromised and the immunocompetent host. J Natl Med Assoc. 2000;92:83-6.
20. Salminen MK, Tynkkynen S, Rautelin H, Poussa T, Saxelin M, Ristola M, Valtonen V, Järvinen A. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study. HIV Clin Trials. 2004;5:183-91.
21. Wolf BW, Wheeler KB, Ataya DG, et al. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem Toxicol. 1998;36:1085-94.
22. Boyle RJ, Robins-Browne RM, Tang MLK. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83:1256-64.
23. Holman RC, Stoll BJ, Curns AT, Yorita KL, Steiner CA, Schonberger LB. Necrotising enterocolitis hospitalisations among neonates in the United States. Paediatr Perinat Epidemiol. 2006. https://doi.org/10.1111/j.1365-3016.2006.00756.x.
24. Sawh S, Deshpande S, Jansen S, Reynaert CJ, Jones PM. Prevention of necrotizing enterocolitis with probiotics: a systematic review and meta-analysis. PeerJ. 2016. https://doi.org/10.7717/peerj.2429.
25. Panigrahi P, Parida S, Nanda NC, Satpathy R, Pradhan L, Chandel DS, et al. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature. 2017. https://doi.org/10.1038/nature23480.